SCHEMBL23554196

SCHEMBL23554196

CCCC(CSCC)C(C)C

nearest known ligand 0.33

Predicted protein targets (top 1)

geneUniProtsupporting neighboursconfidence
TSHR P16473 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22664117 1.00 TSHR (0.31) TSHR
SCHEMBL599955 0.76 TSHR (0.40) TSHR
SCHEMBL16899450 0.76
SCHEMBL28129649 0.71
SCHEMBL83532 0.71
SCHEMBL10662128 0.69 OPRM1 (0.39) TSHR
SCHEMBL16899666 0.69 TSHR (0.30) TSHR
SCHEMBL16899461 0.69
SCHEMBL576072 0.67
SCHEMBL18158037 0.67 METAP2 (0.33)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210187119-A1 Drug-Conjugates, Conjugation Methods, And Uses Thereof VIVASOR, INC. 2021-06-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210187119-A1 Drug-Conjugates, Conjugation Methods, And Uses Thereof PAICS, CES2, DNPEP TSHR 2940/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.